Seagen Inc.

David A Eavarone

Alexey Alexandrovich Lugovskoy

Daniel T Dransfield

Kristan Meetze

Jeffrey Behrens

Ana Paula Galvao Da Silva

Jillian M Prendergast

Julie DeSander

Darius Ghaderi

Mai Zhang

The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.

Glycan-interacting compounds and methods of use

Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.

The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.

Growing community of inventors

North Quincy, MA, United States of America

David A Eavarone